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A novel VIVO–pyrimidinone complex: synthesis,
solution speciation and human serum protein binding†
Gisela Gonçalves,a Isabel Tomaz,a,e Isabel Correia,a Luís F. Veiros,a
M. Margarida C. A. Castro,b Fernando Avecilla,*c Lorena Palacio,c Miguel Maestro,c
Tamás Kiss,d Tamás Jakusch,d M. Helena V. Garciae and João Costa Pessoa*a
The pyrimidinones mhcpe, 2-methyl-3H-5-hydroxy-6-carboxy-4-pyrimidinone ethyl ester (mhcpe, 1), 2,3-
dimethyl-5-benzyloxy-6-carboxy-4-pyrimidinone ethyl ester (dbcpe, 2) and N-methyl-2,3-dimethyl-5-
hydroxy-6-carboxyamido-4-pyrimidinone (N-MeHOPY, 3), are synthesized and their structures determined
by single crystal X-ray diffraction. The acid–base properties of 1 are studied by potentiometric and spec-
trophotometric methods, the pKa values being 1.14 and 6.35. DFT calculations were carried out to deter-
mine the most stable structure for each of the H2L
+, HL and L− forms (HL = mhcpe) and assign the groups
involved in the protonation–deprotonation processes. The mhcpe− ligand forms stable complexes with
VIVO2+ in the pH range 2 to 10, and potentiometry, EPR and UV-Vis techniques are used to identify and
characterize the VIVO–mhcpe species formed. The results are consistent with the formation of VIVO,
(VIVO)L, (VIVO)L2, (V
IVO)2L2H−2, (V
IVO)L2H−1, (V
IVO)2L2H−3, (V
IVO)LH−2 species and V
IVO-hydrolysis pro-
ducts. Calculations indicate that the global binding ability of mhcpe towards VIVO2+ is similar to that of
maltol (Hmaltol = 3-hydroxy-2-methyl-4H-pyran-4-one) and lower than that of 1,2-dimethyl-3-hydroxy-4-
pyridinone (Hdhp). The interaction of VIVO-complexes with human plasma proteins (transferrin and
albumin) is studied by circular dichroism (CD), EPR and 51V NMR spectroscopy. VIVO–mhcpe–protein
ternary complexes are formed in both cases. The binding of VIVO2+ to transferrin (hTF) in the presence of
mhcpe involves mainly (VIVO)1(hTF)(mhcpe)1, (V
IVO)2(hTF)(mhcpe)1 and (V
IVO)2(hTF)(mhcpe)2 species,
bound at the FeIII binding sites, and the corresponding conditional formation constants are determined.
Under the conditions expected to prevail in human blood serum, CD data indicate that the VIVO–mhcpe
complexes mainly bind to hTF; the formation of VIVO–hTF–mhcpe complexes occurs in the presence of
FeIII as well, distinct EPR signals being clearly obtained for FeIII–hTF and to VIVO–hTF–mhcpe species. Thus
this study indicates that transferrin plays the major role in the transport of VIVO–mhcpe complexes under
blood plasma conditions in the form of ternary VIV–ligand–protein complexes.
Introduction
The presence of vanadium in biological systems, its possible
physiological roles and its therapeutic effects regarding its
insulin-enhancing action and anticancer activity have driven a
considerable amount of research. Particular interest has been
devoted to the study of the potential benefits of vanadium
compounds as insulin oral substitutes for the treatment of
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†Electronic supplementary information (ESI) available: ESI-1: Protonated–de-
protonated forms of mhcpe calculated by DFT; ESI-2: experimental and calcu-
lated visible absorption spectra for the VIVO–mhcpe system and discussion of
the plausible binding modes; ESI-3: ternary systems VIVO–amino acid–mhcpe;
ESI-4: A 50 mm quartz cell for circular dichroism spectra measurements; ESI-5:
circular dichroism spectra for the hTF–mhcpe system (UV range); ESI-6: CD
spectra for the apo-hTF (and/or HSA)–VIVOSO4–mhcpe (or –maltol, or –dhp
systems) in the UV range; ESI-7: CD spectra of solutions containing apo-hTF and
additions of solutions containing VVO–mhcpe complexes in the visible range;
ESI-8: spectra of solutions containing apo-hTF, VIVOSO4, Fe
III and mhcpe; ESI-9:
circular dichroism spectra of solutions containing HSA, VIVOSO4 and mhcpe –
far UV range; ESI-10: synthesis of mhcpe (1), dbcpe (2), N-MeHOPY (3) and X-ray
diffraction data. CCDC 926545 (1), 926546 (2) and 926547 (3). For ESI and crys-
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diabetes. Namely the role of the ligand has been a matter of
debate: coordinated ligands should be able to improve the
absorption in the gastrointestinal tract while also facilitating
the transport and uptake of vanadium by the cells, reducing
the dose necessary for producing an equivalent effect when
compared to a vanadium salt/inorganic source.
Research has focused on the development of new and more
efficient insulin-enhancing compounds as well as on under-
standing the mechanism of their action.1–13 The mechanisms
by which vanadium compounds mediate antidiabetic effects
in vivo are not well understood. It is known that vanadate is a
very potent inhibitor of phosphatases and other
phosphorylases,11,14–18 and the key events appear to involve
interactions with protein tyrosine phosphatases and tyrosine
kinases.11,18–20 Several vanadium complexes have been found
to have higher insulin enhancing activities than inorganic oxo-
vanadium(V) or oxovanadium(IV) salts, but probably this
improved efficacy probably relates to the increased bioavail-
ability of the metal ion when involved in a complex rather than
to increased potency at the phosphatase enzyme active
sites.19–23
Among the several complexes exhibiting insulin enhancing
properties, VIVO(maltolato)2 (BMOV) and V
IVO(ethylmaltolato)2
(BEOV) have been extensively studied from the chemical and
pharmacological points of view.8,21–26 Complexes with 3-
hydroxy-4-pyrones (3,4-HP) have also been extensively
studied.19,24–29
Replacement of the O atom of the pyrone ring by a N or
N–R group yields pyridinone derivatives, and both families of
compounds maintain the (O−, O−) binding set, forming quite
stable complexes with many metal ions.28,30 Pyridinones have
been proposed as oral therapeutic chelators for FeIII and AlIII
removal,31,32 and the compound 1,2-dimethyl-3-hydroxy-4-pyri-
dinone (Hdhp – Scheme 1), commercially known as Deferi-
prone®, is used in the treatment of β-thalassaemia.31–33 The
complexation of VIVO2+ and VVO2
+ with dhp was studied in
aqueous solution34–38 and exhibited quite interesting insulin
like properties.12,13,39,40
Aiming at developing ligands with similar structural and
binding ability characteristics of pyridinone and pyrone het-
erocycles, with improved aqueous solubility, we developed a
distinct heterocyclic ligand system of the pyrimidinone type:
2-methyl-3H-5-hydroxy-6-carboxy-4-pyrimidinone ethyl ester, or
mhcpe – Scheme 1 – containing two N atoms in the ring.41
Pyrimidines, by virtue of substituting an additional carbon
atom for a nitrogen atom in the heterocycle ring, reduce the
capacity to tolerate the positive charge resulting from protona-
tion and therefore may possess a more acidic protonation.
However, depending on the nature and position of the substi-
tuting atoms of the ring, and the possibility of formation of
intramolecular H-bonds, the actual protonation constants may
be more or less basic than those of the corresponding pyridine
compounds.
The system VV–mhcpe was previously studied by pH-poten-
tiometry and 51V NMR by some of us, and its cytotoxic activity
was screened with two different cell lines (HeLa tumor cells
and 3T3-L1 fibroblasts).42 The toxic effects were found to be
incubation time and concentration dependent. According to
the IC50 values and the results on reversibility to drug effects,
the VV–mhcpe system showed higher toxicity in the tumor cells
than in non-tumor cells, which may indicate potential anti-
tumor activity. In this work we report the synthesis and charac-
terization of mhcpe, and the study of its interaction with
VIVO2+ in aqueous anaerobic solution, using potentiometric
and spectroscopic techniques.
It has been proposed that in higher organisms the delivery
of vanadium into cells can be promoted by natural carriers
such as plasma proteins, particularly by the high molecular
mass (hmm) blood serum components: human serum trans-
ferrin (hTF) and human serum albumin (HSA).22,23,40,43–50
Transferrin (hTF) is a single-chain glycoprotein containing
around 630 amino acids which are arranged in two similar
lobes, and is important for iron transportation. It is present in
human blood plasma in about 37 μM concentration. It has two
binding sites per protein to accommodate FeIII, one in each
lobe, which is coordinated by two tyrosines, a histidine, an
aspartate and a carbonate anion (the so-called synergistic
anion) in a distorted octahedral geometry.51 The binding
mode of the metal ions at the two sites depends on the nature
of the metal ion, the synergistic anion and the pH, but
binding is generally slightly preferred at the C-terminal than at
the N-terminal.51 In normal serum, only about 30% of the
total binding sites are occupied by iron.7 This means that
there are still sites available for other metal ions (correspond-
ing to ca. 50 μM), without needing to replace the tightly bound
FeIII. In fact hTF can bind strongly to a range of other metal
ions, as is the case of VIVO2+.23,43,48–50
Human serum albumin (HSA) is a globular protein consist-
ing of a single polypeptide chain of 585 amino acids. It is the
most abundant protein in plasma, accounting for ∼60% of
total plasma protein, with a concentration of ca. 0.63 mM,
being the most important nonspecific transporter protein in
the circulatory system.52
Since both albumin and transferrin play important roles in
the distribution and transport of different compounds, they
must be taken into account when evaluating the interactions
and/or speciation of any metal-containing drugs once in
human blood. Besides hTF and HSA other constituents should
also be considered in any model which attempt to elucidate
the fate of vanadium in human blood plasma. Strong evidence
Scheme 1 Molecular formulas of maltol (Hma), Hdhp, 6-carboxamido-5,4-
hydroxypyrimidinones (HOPY compounds) and mhcpe 1. The totally protonated
compounds correspond to HL, HL, H2L
+ and H2L
+, respectively. Unless a specific
protonation state of 1 is needed, this compound will be designated by mhcpe.
The same will be applied to the designations of maltol or dhp.
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has been provided to support that most of the vanadium in
the serum is bound to hTF, even in the absence of
HCO3
−.22,23,40,43,48–57 The results indicate that two vanadium
ions are bound to the metal-ion-free apo-hTF, at the usual
specific FeIII binding sites. Under the physiological conditions,
particularly in the hypothetical situation where the vanadium
concentration is higher than ca. 50 μM, albumin may also par-
ticipate in vanadium binding. If vanadium is introduced in
blood in the form of a VIVO(carrier)2 complex (carrier = biden-
tate ligand), these carrier ligands and/or low molecular mass
(lmm) bioligands may also participate in the transport of
vanadium in blood.23,40,43,45–50
In this work we also report and discuss our findings by CD,
EPR, and 51V NMR spectroscopy regarding the interaction of
VV– and VIV–mhcpe and vanadium–mhcpe complexes with
human serum apo-transferrin (apo-hTF), as well as CD studies
of interaction of VIV-dhp and VIV-maltol with apo-hTF and HSA
in concentrations corresponding to those present in blood
serum.
Results and discussion
Synthesis and characterization
The pyrimidinone mhcpe 1, depicted in Scheme 1, was pre-
pared as outlined in Scheme S-9-1† (see also the Experimental
section), while dbcpe (2) was synthesized from one of the inter-
mediates and N-MeHOPY (3) was obtained from 2, as indicated
in Scheme S-9-1.†41 These compounds were characterized by
1H and 13C NMR, mass spectrometry and by single crystal
X-ray diffraction, and their purity was confirmed by elemental
analysis.
Crystals of 1 (mhcpe), 2 (dbcpe) and 3 (N-Me-HOPY), suit-
able for X-ray diffraction studies, were obtained. Ortep dia-
grams with the molecular structures are depicted in Fig. 1. In
the crystals of mhcpe the N(1) atom is protonated and N(2) is
not protonated. Atoms O(2)–H⋯O(3) are involved in intramole-
cular hydrogen bonds [O(2)–O(3) 2.628(3) Å, H(2O)–O(3) 1.91(4)
Å and O(2)–H(2O)–O(3) 141(4)°] and every two molecules
form a H-bonded dimer in the solid-state (see the ESI†
section). Other intermolecular H-bonds are also observed:
[N(1)–O(1) 2.837(4) Å, H(1A)–O(1) 1.98 Å, N(1)–H(1A)–O(1) 178.0°
and O(2)–O(3) 3.113(4) Å, H(2O)–O(3) 2.42(4) Å, O(2)–H(2O)–
O(3) 139(3)°]. In the crystal packing of mhcpe an offset-face-to-
face (OFF) interaction is observed with a distance between the
centres of both rings of 4.442 Å (Table 1).58
The solid state structure of dbcpe (2) has no hydrogen bond
interactions. In the crystal of N-MeHOPY the hydrogen bond
interactions differ from those of 1. Aromatic–aromatic inter-
molecular interactions are present in the crystal packing of the
crystals of mhcpe and of N-MeHOPY (see the ESI† section),
and a comparative view of the π–π-stacking and hydrogen
bonding interactions in the crystal packings of 1 (mhcpe) and
of 3 (N-MeHOPY) is shown in Fig. S-10-3.†
Solution studies
Ethyl 5-hydroxy-2-methyl-6-oxo-1,6-dihydropyrimidine-4-car-
boxylate – mhcpe. The protonation equilibria were studied in
the pH range of ca. 0.5 to 12 by UV absorption spectroscopy
and in the pH range of ca. 1.8 to 12 by pH-potentiometry, at an
ionic strength of 0.20 M KCl. Individual calibration curves of
EMF vs. [H+] were established for pH values <∼2, valid for the
present medium and electrodes. For this purpose a set of HCl
solutions were prepared with known H+ concentrations, all
with an ionic strength of 0.20 M. This calibration curve was
used for all measurements below ca. pH 2.
Only two protonation steps were observed. Fig. 2 depicts
several of the UV absorption spectra obtained. The protonation
constants of the ligand were calculated with the PSEQUAD
computer program59 using both the experimental UV spectra
and potentiometric titrations, and the results are included in
Table 2. The calculated pKa values from the UV spectra are:
pKa1 = 1.14 and pKa2 = 6.34. The pKa2 calculated from the pH-
metric titrations is 6.36.
1H NMR titration studies carried out in the pH range 1–8
made with solutions containing mhcpe led to inconclusive
results as to where the protonation–deprotonations took place
as the protons on the mhcpe molecule did not afford relevant
information in this regard. To better understand the protona-
tion and deprotonation processes, a thorough conformational
study was carried out for H2L
+, HL and L− by means of
DFT calculations.60 The stability of the several tautomers
Fig. 1 Ortep diagrams (30% probability) of 1 (mhcpe), 2 (dbcpe) and 3 (N-
MeHOPY), showing the atomic numbering scheme. For clarity hydrogen atoms
are omitted.
Table 1 Selected bond lengths [Å] for 1 (mhcpe), 2 (dbcpe) and 3 (N-
MeHOPY). Selected angles are given in the ESI† section
1 – mhcpe 2 – dbcpe 3 – N-MeHOPY
Lengths (Å)
O(1)–C(1) 1.222(4) 1.226(3) 1.2259(15)
O(2)–C(2) 1.330(3) 1.366(3) 1.3463(15)
O(3)–C(6) 1.196(4) 1.182(3) 1.2504(15)
O(4)–C(6) 1.317(4) 1.310(4)
N(1)–C(4) 1.354(4) 1.374(3) 1.3798(16)
N(1)–C(1) 1.357(4) 1.393(4) 1.3965(16)
N(2)–C(4) 1.282(4) 1.302(3) 1.2962(16)
N(2)–C(3) 1.367(4) 1.359(4) 1.3740(15)
C(1)–C(2) 1.433(4) 1.442(4) 1.4549(17)
C(2)–C(3) 1.352(4) 1.357(4) 1.3634(17)
C(3)–C(6) 1.476(4) 1.502(4) 1.4878(16)
C(4)–C(5) 1.478(4) 1.488(4) 1.4913(18)
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considered may depend, to some extent, on solvation and
ionic interactions occurring in solution. Since the solvent is
water, solvation will rely on H-bonds established between the
solute and solvent; as the comparison is made between
isomers, part of the solvation effects are expected to cancel,
and the energy differences calculated with implicit solvent
corrections (PCM model, see the DFT computational details
section) should give important clues to understand the pre-
dominant species in aqueous solution, in each case.
The structures of several tautomeric forms were calculated
in a thorough search for each stoichiometry H2L
+ (a total of 8
tautomers), HL (a total of 10 tautomers) and L− (a total of 5
tautomers). The structures presented in Scheme 2 and dis-
cussed above correspond to the most stable tautomers, with
energy differences less than 10 kcal mol−1 (see the section
ESI-1†) with respect to the most stable tautomer of each stoi-
chiometry. Additional metric and electronic parameters for the
optimized structures are provided in the ESI† section, as well
as the atomic coordinates for all optimized species. Partial
charges and Wiberg indexes are also given in the section
ESI-1.†
For 3-hydroxy-4-pyridinone derivatives there is some con-
sensus in the literature that the protonation of the HL species
takes place mainly on the N atom of the ring and the pKa1
values obtained, in the range 3.5–3.8, are several orders of
magnitude higher than those for 3-hydroxy-4-pyrones.28,35 This
may be explained considering that in the H2L
+ form of the
compounds, the N atom is more efficient in delocalizing the
positive charge in the ring than the O atom. Accordingly, for
the H2L
+ form of the pyrimidinone mhcpe the most stable
form (DFT-2 in Scheme 3) corresponds to the tautomeric form
where both N-atoms are protonated. The tautomeric form
Fig. 2 UV spectra of ca. 10−4 M solutions of mhcpe, (A) pH 0.9 to 5.20; (B) pH 5.49 to 8.24; calculated UV spectra for (–-) H2L
+ (in A) and for (•••) HL and (+++) L−
species (in B) using the PSEQUAD program59 are also included. The arrows indicate the spectral changes observed upon increasing the pH.
Table 2 Protonation and formation constants obtained from potentiometric
and spectrophotometric data with the PSEQUAD computer program59 for
aqueous solutions containing mhcpe and VIVO(ClO4)2 at 25 °C and I = 0.2 M KCl
HnL Log β pKa
HL 6.35 (±0.06) 6.35
H2L 7.48 (±0.15) 1.14
(VO)pLqHr Log β (V
IVO2+)a
(VO)L 6.28 (±0.10)
(VO)L2 11.67 (±0.10)
(VO)L2H−1 5.02 (±0.10) ∼6.7
(VO)2L2H−2 5.1 (±0.5)
(VO)2L2H−3 −0.08 (±0.2) ∼5.2
(VO)LH−2 −5.24 (±0.10)
a The values given as (±x) for the vanadium complexes are not the
standard deviations obtained directly by the PSEQUAD program; the
values given account for the range in the log β values obtained in the
several equilibrium models tested using the potentiometric and
spectrophotometric data. These values are thus higher than the SDs
given by the individual calculations of PSEQUAD.
Scheme 2 The most stable structures calculated for H2L
+ (top), HL (center),
and L− (bottom). Solvent (water) effects were considered in the energy calcu-
lations. The stability difference between tautomers (kcal mol−1) is indicated for
each stoichiometry, the structures depicted on the left side being the most
stable ones for each protonation state.
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where N(2) is protonated and N(1) is deprotonated (DFT-1) is
less stable by 5.6 kcal mol−1, and the form where atom N(2) is
deprotonated and atom N(1) is protonated (DFT-3) is less favor-
able by +9.7 kcal mol−1.
The pKa2 values obtained for pyridinones, in the range
9.7–9.9,28,35 show that pyridinones are stronger bases than
pyrones. This has been attributed to the delocalization of the
partial negative charge to the O atom in position 4 of the
ring.28,35 For the HL species of mhcpe the most stable tauto-
mer corresponds to the one characterized by X-ray diffraction.
The tautomer with N(1) deprotonated and atom N(2) proto-
nated is less stable by 4.6 kcal mol−1 (DFT-6), and the tauto-
mer with both N atoms deprotonated is less favourable by
8.4 kcal mol−1 (DFT-5).
For the L− species, the most stable tautomer corresponds to
DFT-9, where the O-atoms that may coordinate to metal ions
are not protonated. The other two tautomers present similar
stabilities: in DFT-8 (+4.2 kcal mol−1) the negative charge is de-
localized over the ring and atom O(1), and in DFT-7 (+5.3 kcal
mol−1) the atom O(1) is protonated and the H-bond O(2)–H⋯
O(3) is not present, but instead a relatively strong H-bond
involving O(1)–H⋯O(2) is predicted (dOH–O = 1.713 Å).
VIVO–mhcpe complexes
Structure and binding constants. The mhcpe ligand binds
VIVO2+ reasonably well at low pH. Fig. 3 includes visible
spectra (Vis spectra) of solutions containing VIVO2+ and mhcpe
with a ligand-to-metal molar ratio (L : M ratio) of 2.76. At low
pH values, e.g. ∼1.0, the UV-Vis spectra already differ from the
spectrum of the free VIVO2+ ion (in fact: [VIVO(OH)5]
2+), namely
in the 600–900 nm range, clearly indicating extensive complex
formation at this pH. Band II (dxy→ dx2−y2) and charge-transfer
bands progressively build up at ∼480 nm, bathochromic
effects being observed with an increase in pH, and band
I (dxy → dxz,dyz)
61 also increases its intensity and also shows a
red shift up to pH = 6.68, as highlighted by the arrows in Fig. 3.
Fig. S-2-1† includes representative Vis spectra for pH > 6.6.
Globally the Vis spectra change significantly as the pH is
increased particularly for pH > ca. 7, but do not change much
in the pH range ca. 4.5–6.5. Moreover, while up to pH 7.2 the
Vis spectra do not change much with changes in the L : M
ratio [varying the CVO from 2 to 6 mM keeping Cmhcpe approxi-
mately constant] indicating that no oligomeric species form,
for pH > 7.5 similar types of experiments show changes indi-
cating the formation of oligomeric species, and hydrolysis for
pH > 8–9. The extension of the hydrolytic processes depends
on the L : M ratio used.
The complex formation constants were calculated with the
PSEQUAD computer program59 from the potentiometric titra-
tion data at different CVO, Cmhcpe and L :M ratios (see the
Experimental section). The best model refined from experi-
mental data includes stoichiometries (oxidation state and
charges omitted for clarity): VO, (VO)L, (VO)L2, (VO)2L2H−2,
(VO)L2H−1, (VO)2L2H−3 and (VO)LH−2. The log β of a few other
stoichiometries could be obtained in some calculations, but
either they were obtained with high standard deviations (SD)
and/or they were not obtained with consistent values and/or they
did not improve the fitting parameter, and were thus ruled out.
The PSEQUAD computer program and the Vis spectra
obtained under different conditions (CVO, Cmhcpe, L : M ratios
and pH values) were also used to calculate the log β and/or the
spectrum of each individual species formed. The calculated
log β values calculated from spectral data agree well with those
obtained from the pH-potentiometry (within ±0.1 log unit),
and Vis spectra (included in the ESI† section) in agreement
with the experimental data recorded could be calculated for
almost all species included in the equilibrium model; this con-
firms that the speciation model proposed and the log β values
calculated are correct and reliable. These data are included in
Table 2 and a concentration distribution diagram is presented
in Fig. 4.
It is clear from the speciation diagram that the mhcpe
ligand forms quite stable complexes with VIVO2+ in a wide pH
range, its hydrolytic products only forming in measurable con-
centration for pH > 7.5. At pH ∼ 7 VIVO2+ is chelated in solu-
tion by mhcpe as (VIVO)L2, [(V
IVO)L2H−1]
−, and [(VIVO)2L2H−3]
−
complexes. The pKa of the process (V
IVO)L2 ⇄ (V
IVO)L2H−1
− +
H+, corresponding to ca. 6.7, suggests the deprotonation of a
coordinated water molecule from (VIVO)L2, and an OH
− is thus
expected in the coordination sphere of [(VIVO)L2H−1]
−. The Vis
spectra calculated for each stoichiometry with PSEQUAD are
consistent with experimental data and are obtained with good
SDs and fitting parameters. Only for the (VO)2L2H−2 stoichi-
ometry the Vis spectra calculated show some parts with a
negative extinction coefficient (i.e. negative values for ε22−2,
not shown) which is most likely due to the low concentration
of this species under all experimental conditions used; thus it
is not surprising that the Vis spectrum of (VO)2L2H−2 cannot
be/is not calculated adequately.
Fig. 3 Representative Vis absorption spectra recorded with aqueous solutions
containing VIVO2+ and mhcpe at L : M = 2.76 and CVO = 5 mM, upon increasing
the pH from 0.98 to 6.68. The spectrum of [VIVO(H2O)5
2+] (•••) is also included
for comparison.
Scheme 3 Proposed binding modes for the monomeric complexes that form
in the VIVO–mhcpe system in aqueous solution (see the text and section ESI-2†).
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Plausible binding modes. EPR spectra were measured in
“frozen” solution (77 K) to confirm the speciation model and
to elucidate binding modes for each species. Some of the EPR
spectra obtained for the VIVO–mhcpe system, in the range cor-
responding to MI = 5/2 and 7/2 (in the high field region of the
spectrum), are depicted in Fig. 5. Table 3 summarises spin
Hamiltonian parameters obtained in the VIVO–mhcpe system
from the simulation of the EPR spectra.63
Four main species, designated as I–IV and assigned to stoi-
chiometries (VO)L, (VO)L2, (VO)L2H−1 and (VO)LH−2, can be
identified as the pH is increased from 2 to 11 (Fig. 5, Table 3).
The EPR spectral intensity decreases slightly in the pH range
4–6, and remarkably for pH > 7, in agreement with the for-
mation of two dinuclear species: (VO)2L2H−2 (present in very
low concentration) and (VO)2L2H−3, the latter probably being
responsible for the broad weak feature detected at pH ca. 7.5
(at its maximum concentration) identified as IIIA in Fig. 5.49,64
VIVO-hydrolysis (accounted here by the formation of EPR-silent
[(VIVO)2(OH)5
−] and EPR-active [VIVO(OH)3
−]) species61,62
become important for pH > 9.5. At high pH (ca. 11), species IV,
corresponding to (VIVO)L2H−1, is probably superimposed by
[VIVO(OH)3
−] signals, which can be indicated by a slight
decrease in the Az value obtained in the simulation of the spec-
trum at pH = 11.30 (Az
est for [VIVO(OH)3
−] = 161.7 × 10−4 cm−1)
and by a slight line broadening.
An additivity rule was developed for VIVO-systems11,65,66 to
estimate the hyperfine coupling constant Az
est, based on the
contributions Az,i of each of the four equatorial donor groups
{Az
est = ΣAz,i, i = 1 to 4}, the estimated accuracy of Azest being ±3
× 10−4 cm−1. No Az,i data have been presented in the literature
66
for ligands such as pyridones, pyridinones or pyrimidinones,
but data are available for the contribution to Az from the equa-
torial Oδ− (Az
O−) for maltol67 and other pyridinones.28 For (VIVO)
L2 complexes with bidentate ligands there is the possibility of
the formation of at least two types of isomeric complexes: cis-
(VIVO)L2 (three O
δ− donors bound equatorially and one axially)
and trans-(VIVO)L2 (all O
δ− donors bound equatorially). These
can be frequently distinguished by EPR and care must be taken
when estimating correct values for Az
O−.
In Scheme 3 we depict the most plausible binding modes
for the present VIVO–mhcpe system, and in the ESI† section we
present a detailed discussion, based on the EPR data and addi-
tivity rule, of how we estimated Az
O− values for the mhcpe
ligand as well as a discussion on how these binding sets were
established.
Fig. 5 High field region of the 1st derivative EPR spectra (77 K) of frozen
aqueous solutions (with 5% DMSO) containing VIVO2+ and mhcpe at several pH
values, A: CVO ≈ 5 mM and L : M = 3 and B: CVO ≈ 4 mM and L : M = 4. The spin
Hamiltonian parameters obtained for species I–IV from simulation of the experi-
mental spectra are presented in Table 3.
Table 3 Spin Hamiltonian parameters (gz and Az) obtained for the species formed in the V
IVO–mhcpe system in aqueous solution. The EPR parameters were
obtained by simulation of the experimental EPR spectra recorded for frozen aqueous solutions (containing 5% DMSO) with the computer program of Rockenbauer
and Korez.63 Oδ− refers to the O-cathecolate type donors from the mhcpe ligand. Structures for the proposed binding modes are included in structures for the pro-
posed binding, Scheme 3
Complex EPR species gz Az/×10
4 cm−1 Proposed binding set
(VO)Lu[(VIVO)L]+ I 1.937 178.6 (Oδ−, Oδ−, 2 × H2O)equat
(VO)L2u[(V
IVO)L2] II 1.942 171.3 (3 × O
δ−, H2O)equat(O
δ−)axial
(VO)L2H−1u[(V
IVO)L2(OH)]
− III 1.944 169.4 (3 × Oδ−, HO−)equat(O
δ−)axial
(VO)LH−2u[(V
IVO)L(OH)2]
− IV 1.943 167.0 (2 × HO−, 2 × Oδ−)equat
Fig. 4 Species distribution diagram for the complexes formed in the VIVO–
mhcpe system for solutions with CVO = 5 mM and L :M = 2 (25 °C and I = 0.2 M
KCl). Charges are omitted for simplicity. (VO) refers to the aquocomplex [VIVO-
(H2O)5]
2+. Dotted lines above pH ca. 9 account for the lower accuracy of the for-
mation constants for VIVO-hydrolysis species [(VIVO)2(OH)5
−]nu(VO)2H−5 and
[VIVO(OH)3
−]u(VO)H−3.
61,62
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Comparison of the binding ability of VIVO2+ to mhcpe, dhp
and maltol
Considering the formation constants included in Table 2 for
VIVO–mhcpe complexes, and those for VIVO–dhp35 and VIVO–
maltol,68 and taking into account the hydrolytic VIVO-species
and protonation constants of the ligands, the −log[VIVO2+]
(= pVO) may be obtained, thus giving a measure of the binding
ability of these ligands towards VIVO2+. The values calculated
are plotted in Fig. 6. It may be seen that mhcpe and maltol
have a quite similar binding ability towards VIVO2+ in the pH
range 2–10, while that of dhp is significantly higher, particu-
larly for 3 < pH < 6.
Considering the role of the ligand as a carrier for the metal
ion (improving its absorption and transport to the target
tissues/cells) an adequate binding ability is critical: the ligand
is expected to bind VIVO2+ (in this case) efficiently enough to
prevent hydrolysis and other side-reactions while allowing its
release when appropriate. In this context, maltol being a
proven effective carrier ligand for VIVO2+, and mhcpe exhibit-
ing a similar adequate binding ability, we also expect this
ligand to release the metal ion in the presence of adequate
competitive bioligands.
Ternary systems VIVO–amino acid–mhcpe
Following administration (either oral or by intravenous injec-
tion), any pharmaceutical will eventually be transported and
distributed within the living system by the blood. If a
vanadium complex, e.g. of VIVO(carrier)2 type, as is the case of
VIVO(mhcpe)2, is taken orally or injected, during its transport
in the blood stream complex formation with the serum com-
ponents must be considered, namely with (i) some of the lmm
constituents (the most potent binders are probably the nega-
tively charged O donor-containing ligands), such as lactate,
phosphate, oxalate and citrate, designated here as ligands B,
and with (ii) the hmm protein constituents, e.g. human serum
albumin, immunoglobulin G and transferrin. In this work we
mainly address the binding of vanadium–mhcpe to hTF.
As mentioned above, in iron bound hTF each lobe contains
a distorted octahedral FeIII binding site consisting of two Tyr,
one His, one Asp residues, and one bidentate carbonate anion,
the two binding sites being similar. To test the formation of
ternary (and quaternary) VIVO-complex species in solution,
namely including the mhcpe ligand, some model systems
(L-His, L-Tyr, L-Asp, Gly-L-His, Gly-L-Asp, L-Asp) were evaluated
at pH ca. 7.2 by measuring their CD spectra in solution. Most
of these results are included in the ESI-3† section.
The degree of complex formation in solutions only contain-
ing VIVO2+ and amino acids in the pH range 6–8 with L : M
ratios up to 4 is usually low, VIVO-hydrolytic products normally
predominate and often VIVO(OH)2 precipitates.
61,62 Adding
mhcpe to these solutions the degree of formation of VIVO-
hydrolytic species decreases significantly and ternary species
typically form, probably VIVO–mhcpe–amino acidato com-
plexes. In fact, if mhcpe is added to solutions containing
VIVO2+ and several amino acids, e.g. L-His and L-Asp, the CD
signal in the visible range increases significantly and the
pattern of the CD spectra differs from those observed for
the VIVO(amino acidato) or VIVO(amino acidato)2
complexes.61,62,69–75 In Fig. 7 we present one such example:
the intensity of the CD signal corresponding to spectrum c
(VIVO :mhcpe : L-His at 1 : 1 : 3 ratio) is much higher than in
the absence of mhcpe, where VIVO2+ is extensively hydrolysed.
Upon addition of L-Asp to the solution of spectrum c, the CD
signal changes, yielding spectrum d, suggesting the formation
of distinct optically active complexes. In section ESI-3† several
similar experiments are also described. Globally these indicate
that ternary VIVO–mhcpe–LIG complexes significantly form
when LIG is L-His or L-Asp, but not when LIG corresponds to L-
Tyr, Gly-L-Asp, lactate or citrate.
Fig. 6 Plot of −log[VIVO2+] (= pVO) for solutions containing VIVO–mhcpe com-
plexes, and those for VIVO–dhp and VIVO–maltol (see text). The plot was calcu-
lated taking CVO = 1 mM and CL = 2 mM, considering the formation constants
obtained in this work and elsewhere.35,68
Fig. 7 CD spectra in the 400–800 nm range of solutions containing (a) L-His,
(b) VIVO : mhcpe : L-His = 1 : 1 : 3 at pH = 3.0, (c) VIVO :mhcpe : L-His = 1 : 1 : 3 at
pH = 7.2 and (d) VIVO : mhcpe : L-His : L-Asp = 1 : 1 : 3 : 3 at pH = 7.2. The concen-
tration of L-His or L-Asp is 6 mM (when present, CVO = Cmhcpe = 2 mM). The
solvent is water and the optical path was 10 mm.
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Interaction of vanadium–mhcpe complexes with apo-
transferrin
CD spectroscopy is frequently used to monitor protein–drug
interactions by following changes in the protein spectrum in
the wavelength range 190–350 nm. In particular, the protein
spectrum in the 200–250 nm range yields information on its
secondary structure and on the changes it undergoes upon the
binding of a compound, while the CD signal in the range
250–350 nm can be traced to the contribution from aromatic
residues (Phe, Tyr, Trp) of the protein. Above 350 nm the
protein is CD silent. However, in the case of the interaction of
metal complexes, an induced CD signal (ICD) – resulting from
chirality that is transmitted to metal-related electronic tran-
sitions – can be observed only if it binds in close proximity to
chiral groups (this is what is observed in Fig. 9). The develop-
ment of an ICD signal yields clear evidence of a strong inter-
action between the protein and the complex. The interaction
of vanadium–mhcpe complexes with apo-human serum trans-
ferrin (hTF) was studied by monitoring the effect of both
VIVO2+ (added as an inorganic salt) and complexes of VIVO–
mhcpe. Results on the interaction of mhcpe alone with the
protein are included in the ESI† section (Fig. S-5-1 and S-5-2†).
CD spectra of solutions of apo-human serum transferrin
(ca. 5 μM) at pH 7.4 practically do not change in the
200–250 nm range, where the protein has intrinsic electronic
transitions, upon stepwise addition of VIVOSO4 up to a molar
ratio of VIVO : hTF of 1 : 1. However, upon further additions of
VIVOSO4 up to a molar ratio of 10, the |Δε| increases (Fig. S-7-
4†), although the global pattern of the CD spectra does not
change. Part of these changes are probably due to the presence
of VV-species, formed by oxidation of VIVO. In a similar exper-
iment but upon stepwise additions of a solution containing
VIVOSO4 and mhcpe in a 1 : 2 molar ratio at pH 7.4, the CD
spectra also practically do not change up to a molar ratio of
VIVO : hTF of 2; further additions of VIVO(mhcpe)2 produced
changes (Fig. S-7-5†) but much less pronounced than in the
absence of mhcpe.
Upon the stepwise addition of mhcpe up to a mhcpe : hTF
molar ratio of 10 : 1, ChTF ≈ 100 μM, in either Hepes-S or
Hepes-CL buffer (CL buffer: similar to Hepes-S but also con-
taining citrate and lactate, see the Experimental section), no
significant changes are seen in the CD spectra in the
250–400 nm range (see Fig. S-5-1 and -2†). This means that
mhcpe does not interact strongly with hTF under these exper-
imental conditions. In contrast, if a 1 : 1 or 1 : 2 VIVO :mhcpe
solution is progressively added to apo-hTF, the CD spectra
show important changes (see Fig. 8), particularly in the wave-
length range 310–360 nm where the protein alone shows no
CD signal.
The induced CD band at ca. 300–360 nm (centered at
∼330 nm), clearly observed in Fig. 8, could be due to mhcpe
absorption (see Fig. 2), and indicates that the mhcpe ligand is
interacting closely with hTF; otherwise no CD band would be
visible in this wavelength range. As this band is only observed
when VIVO2+ and mhcpe are both present, this implies that
mhcpe is also bound to VIVO. Additional proof of this binding
is given below. Similar measurements made in Hepes-S buffer
(section ESI-6†) show very similar CD spectra, but the Δε
values in the 320–360 nm range are ca. 25% higher, possibly
because the citrate and lactate present in the Hepes-CL buffer
partly sequester the VIVO2+, decreasing the amount bound to
hTF. It is interesting to note that quite similar CD spectra,
giving equivalent information, were obtained with solutions
containing (i) VIVOSO4, maltol and apo-Tf and (ii) V
IVOSO4,
dhp and apo-hTF (section ESI-6†), thus also confirming the
formation of ternary VIVO–maltol–hTF and VIVO–dhp–hTF
complexes.57
Fig. 9 presents CD spectra (recorded with a 50 mm optical
path quartz cell, see the section ESI-4†) in the 400–1000 nm
range (designated here as the Vis range) of solutions contain-
ing apo-hTF and either (A) one equiv. or (B) two equiv. of
VIVOSO4, and progressively adding mhcpe. All bands observed
for λ > 500 nm correspond to d–d transitions of the VIV center
of the VIVO unit. In this wavelength range CD signals can only
be observed if the VIVO-species present are in close-interaction
with chiral protein groups. Different CD signals must corre-
spond to different types of V-species present and interacting
with chiral protein groups.61,62,69–73 Fig. 9 clearly shows that
the VIVO–protein CD spectra totally change upon adding
mhcpe (spectra c–f ), and therefore different VIVO-species are
formed. Namely, the pattern of the CD spectra corresponding
to (VIVO)1(hTF) and (V
IVO)2(hTF) complexes, due to one or two
VIVO-centres bound to apo-hTF in the iron binding sites, is no
longer observed, thus implying that the mhcpe ligand binds to
the VIVO centres which probably remain bound in the iron
binding sites.
Fig. 8 CD spectra in the 250–400 nm range of solutions containing apo-hTF
(CHTF = 100 μM) and after stepwise additions of a solution containing VIVOSO4
and mhcpe in a 1 : 2 molar ratio in Hepes-CL buffer. (a) apo-hTF; (b) apo-hTF :
VIVO : mhcpe = 1 : 1 : 2; (c) apo-hTF : VIVO :mhcpe = 1 : 2 : 4; (d) apo-hTF : VO :
mhcpe = 1 : 3 : 6; (e) apo-hTF : VO : mhcpe = 1 : 6 : 12. The spectra were recorded
with a 2 mm optical path quartz cell. For λ < 275 nm the optical density is too
high; consequently the noise in the CD signal increases. Under similar con-
ditions, the CD spectra of apo-hTF solutions (ChTF = 100 μM) do not show signifi-
cant changes up to a VIVO : hTF molar ratio of 5, the spectra being equal to
spectrum a.
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The addition of up to 1.0 equiv. of mhcpe (relative to the
VIVO present) causes a total change in the pattern of the ICD
bands, namely the d–d bands Ib and Ia change signal, and
band II becomes more negative,61 but further additions of
mhcpe do not change much the ICD bands measured. Quite
similar CD spectra and trends were found when adding solu-
tions containing either VIVOSO4 and mhcpe in 1 : 1 or
1 : 2 molar ratios to solutions containing apo-hTF at pH 7.4
(see the section ESI-7†). All observations suggest the formation
of complexes with stoichiometries (VIVO)1(hTF)(mhcpe)1,
(VIVO)2(hTF)(mhcpe)1 and (V
IVO)2(hTF)(mhcpe)2.
Fig. 10 depicts several EPR spectra of frozen solutions con-
taining apo-hTF and VIVOSO4, and of solutions containing
apo-hTF, VIVOSO4 and mhcpe. The EPR spectra differ when the
mhcpe ligand is present, as was observed with the CD spectra
(above), clearly indicating that a modification of the VIVO-
binding set changes when mhcpe is added to solutions con-
taining apo-hTF and VIVOSO4. The number of distinct species
detected and spin-Hamiltonian parameters do change, but as
most donor groups give rather similar contributions to the gz
and Az values, the modifications observed on the spectral lines
are not drastic. Moreover, in the case where mhcpe is present
we can observe the presence of the two new environments that
we have labelled C and D, characterized by distinct Az values
(Table 5). The environment corresponding to C appears to be
preferred over D. This behaviour was observed in both buffers,
Hepes-S and Hepes-CL (the g and A values in both are equal),
but the formation of D is slightly enhanced when the Hepes-
CL buffer is used.
Calculation of conditional stability constants. The stability
constants of the (VIVO)–hTF and (VIVO)2–hTF species were
determined40 from the CD spectra and the isotropic/anisotro-
pic EPR signal ratios with the computer program PSEQUAD59
as: log K1 = log β1 = 13.4 and log K2 = 11.9 (log β2 = 25.3),
respectively; these are conditional stability constants only valid
at pH 7.4. Sanna et al.76 obtained similar log β1 and log β2
values.
The stability constants of the ternary species
(VIVO)p(hTF)1(mhcpe)r were determined from the experimental
CD spectra with different VIVO–hTF–mhcpe molar ratios, also
using the computer program PSEQUAD. The protonation con-
stants of the ligands, the stability constants of the VIVO–
mhcpe complexes, and the hydrolytic constants of VIVO were
all taken into account as fixed parameters in the calculations.
The conditional stability constants for the binary species
(VIVO)–hTF and (VIVO)2–hTF were also considered with the
known values. The stability constants calculated are presented
in Table 4, and a speciation profile is depicted in Fig. 11 for an
hTf concentration close to that of the human plasma. The
Fig. 9 CD spectra in the 400–1000 nm range of solutions in Hepes-S buffer containing (A) apo-hTF and VIVOSO4 (CHTF = CVO = 750 μM) (a) apo-hTF; (b) apo-hTF :
VIVO : mhcpe = 1 : 1 : 0; (c) apo-hTF : VIVO : mhcpe = 1 : 1 : 0.5; (d) apo-hTF : VIVO : mhcpe = 1 : 1 : 1; (e) apo-hTF : VIVO : mhcpe = 1 : 1 : 1.5; (f ) apo-hTF : VIVO :mhcpe =
1 : 1 : 2, and (B) apo-hTF and VIVOSO4 (CHTF = 750 μM, CVO = 2 × 750 μM), and progressively adding mhcpe (a) apo-hTF; (b) apo-hTF : VIVO :mhcpe = 1 : 2 : 0; (c) apo-
hTF : VIVO : mhcpe = 1 : 2 : 0.5; (d) apo-hTF : VIVO :mhcpe = 1 : 2 : 1; (e) apo-hTF : VIVO : mhcpe = 1 : 2 : 1.5; (f ) apo-hTF : VIVO :mhcpe = 1 : 2 : 2. The spectra were
recorded with a 50 mm optical path quartz cell (see the section ESI-4†).
Fig. 10 First derivative EPR spectra of frozen solutions of apo-hTF (ChTF =
750 μM) and VIVOSO4 (CVO = 2 × ChTF), labeled 1 : 2, and of solutions containing
apo-hTF (ChTF ≈ 0.75 mM), VIVOSO4 (CVO = 2 × ChTF) and mhcpe (Cmhcpe = CVO or
Cmhcpe = 2 × CVO), labeled 1 : (2 : 2) and 1 : (2 : 4). All solutions contain the
Hepes-CL buffer at pH ∼ 7.4. In the high-field region amplifications of the
spectra are included, all with solutions containing apo-hTF (ChTF ≈ 0.75 mM)
and with concentrations of VIVOSO4 and mhcpe according to the molar ratios
indicated.
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corresponding CD spectra were also calculated and are shown
in Fig. S-7-3.† As expected, the profiles observed for the calcu-
lated CD spectra for the VIVO–hTF or VIVO–hTF–mhcpe species
differ significantly, indicating a very distinct environment of
VIVO in the presence and in the absence of the mhcpe ligand.
Several questions remain open, e.g. whether ternary or qua-
ternary VIVO-complexes form, which hTF donor groups/resi-
dues bind to the metal centre and if hTF can assume (or not)
the closed conformation recognizable by the transferrin recep-
tor in the presence of mhcpe (probably yes).57
Interaction of vanadium–mhcpe complexes with transferrin in
the presence of iron
As mentioned above, in normal serum, only about 30% of the
total FeIII binding sites are occupied by this metal ion. As the
hTF concentration in blood serum is ca. 37 μM this means
that there are sites available for binding other metal ions, cor-
responding to ca. 50 μM, with no need to replace the tightly
bound FeIII. Therefore, hTF can also bind strongly to a range
of other metal ions, as is indeed the case of VIVO2+.
In solutions containing VIVO2+ and hTF under conditions
where there are enough free available sites for the binding of
all VIVO2+ present, we observed that this metal ion is more
easily oxidized to VV than in the absence of FeIII. This is an
interesting observation considering that VIV binds to hTF
much more strongly to hTF than VV.40,47 A similar effect was
observed in solutions also containing mhcpe, maltol or dhp.
Fig. SI-8-1† includes CD spectra of solutions containing apo-
hTF and after stepwise additions of a solution containing
VIVO2+ and mhcpe with a 1 : 2 molar ratio. These spectra are
similar to those presented in Fig. 9. Upon adding a solution
containing an amount of FeIII equivalent to 30% of the hTF
FeIII-binding sites, the ICD bands in the 500–1000 nm range,
assigned to VIVO d–d transitions, decrease continuously with
time due to the relatively fast oxidation of VIVO- to VV-species
(Fig. SI-8-1†). This relatively fast oxidation occurs despite the
hTF present in solution contains enough binding sites to bind
all VIVO and FeIII added.
In Fig. 12 spectrum 1 corresponds to the EPR spectrum of a
frozen solution containing apo-hTF (ChTF = 0.75 mM), V
IVOSO4
(CVO = 1.50 mM) and Fe
III (CFe = 0.45 mM) at pH 7.4; the pres-
ence of both the VIVO–hTF and FeIII–hTF EPR signals is clearly
seen. An EPR spectrum very similar to this one was recorded
with a solution containing apo-hTF and VIVOSO4 (1 : 2 molar
ratio), and upon addition of FeIII to this solution. The FeIII
added removed an equivalent amount of VIVO2+ from the hTF
Fe-binding sites and the intensity of the VIVO-EPR spectrum
decreased accordingly. The excess VIVO removed by the
addition of FeIII or that present in the bulk solution of spec-
trum 1 of Fig. 12 is not detected as it is in the form of EPR
silent species and/or was oxidized to vanadate species.61,62
Upon addition of mhcpe the VIVO-EPR spectrum changes
due to the formation of VIVO–hTF–mhcpe complexes. As men-
tioned above, in the presence of FeIII the ICD spectra in the
visible range decrease rather fast and the intensity of the
VIVO-EPR progressively decreases accordingly. The FeIII-EPR
spectra show some changes probably due to the formation of
FeIII–mhcpe complexes.
Fig. 11 Species distribution diagram for the complexes formed at pH 7.4 in
the VIVO–apo-hTF–mhcpe system for blood plasma conditions (Capo–hTF = 40 μM
and CVO = 80 μM), based on the stability constants presented in Table 5.
Table 4 Conditional formation constantsa determined for the ternary
[(VIVO)p(hTF)q(mhcpe)r] system (p, r = 0–2; q = 1) using CD data and the compu-
ter program PSEQUAD59 (in Hepes-S buffer at pH 7.4 and t = 25 °C)
(VO)p(hTF)q(mhcpe)r Composition (p,q,r) Log βpqr
(VO)(hTF) (1,1,0) 13.37
(VO)2(hTF) (2,1,0) 25.21
(VO)(hTF)(mhcpe) (1,1,1) 18.2(2)b
(VO)2(hTF)(mhcpe) (2,1,1) 31.0 (1)
b
(VO)2(hTF)(mhcpe)2 (2,1,2) 35.5 (1)
b
a For the definition of ‘conditional formation constants’ used, see the
Experimental section. b The values given between parentheses are the
standard deviations obtained directly by the PSEQUAD program
multiplied by three.
Table 5 Spin Hamiltonian parameters (gz and Az) obtained for the species
formed in the VIVO–apo-hTF–mhcpe–Fe system in aqueous solutions containing
the Hepes-S buffer at pH 7.4. The EPR parameters were obtained by simulation
of the experimental EPR spectra recorded for frozen aqueous solutions with the
computer program of Rockenbauer and Korez59
EPR species gz Az (×10
4 cm−1)
A 1.938 167.7
Aa 1.938 168.0
Ab 1.937 168.3
B 1.940 170.7
Ba 1.938 170.0
B1
b 1.941 170.3
B1
c 1.941 170.5
B2
b 1.937 172.4
B2
c 1.935 171.8
Cd 1.941 170.4
Dd 1.946 166.5
E (contains FeIII) 1.941 168.2
a From Mustafi et al.77 b From Chasteen et al.78 c From Jakusch et al.40
d The spin Hamiltonian parameters (gz and Az) obtained for these
species are identical in measurements in Hepes-S and Hepes-CL
buffers.
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The 51V NMR spectrum of the solution of spectrum 3 of
Fig. 12 was also measured and two resonances were observed:
the signal corresponding to VV–hTF species (at δ = −532 ppm)
and a low intensity signal corresponding to VV–mhcpe com-
plexes42 (at δ ≈ −538 ppm). This means that upon addition of
FeIII to the solution containing apo-hTF and VIVO2+, in a
1 : 2 molar ratio, the VIVO2+ is oxidized to some extent to
VV-species which in turn bind to hTF. In the ESI† section
additional information regarding EPR and 51V NMR spectra
measured is included.
Upon addition of FeIII to solutions containing apo-hTF and
VIVOSO4 (1 : 2) – spectrum 1 of Fig. 13, the V
IVO-EPR spectrum
changes significantly: (i) the global intensity decreases, (ii) the
relative intensity of resonances assigned to the VIVO binding to
the C-terminal site (the B component in the VIVO-EPR spec-
trum, see Fig. 15 and 16, which binds FeIII more strongly)
decreases drastically. Comparing the VIVO-EPR spectra 2 and 3
of Fig. 13 (with [hTF : VIVO :mhcpe : Fe] = 1 : 1.4 : 2.8 : 0.6 just
after the FeIII addition, and the same sample recorded 60 min
later), it may be noticed that: (i) the intensity decreases signifi-
cantly, this being compatible with oxidation of part of the VIVO
present; and (ii) the Az values slightly decrease. From obser-
vation of spectra 2 and 4–6 of Fig. 13 it can also be concluded
that the spin-Hamiltonian parameters of the species present
are slightly different, suggesting the presence of new species,
designated by C and D, distinct from those detected in solu-
tions of VIVO2+ and mhcpe at pH ≈ 7.4 (e.g. spectrum 7). No
51V NMR signal corresponding to any hTF–VV–mhcpe species
was detected in this or in other experiments.
In Table 5 the spin Hamiltonian parameters obtained for
the species formed in the VIVO–apo-hTF–mhcpe–Fe system are
summarized. The EPR signal corresponding to the VIVO-
species E differs significantly from those labelled as C or D,
but corresponds to parameters very similar to those of A (or B),
assigned to (VIVO)–hTF species. However, it is not likely that
they indeed correspond to (VIVO)n–hTF complexes as the CD
spectrum measured differs from those of (VIVO)n–hTF com-
plexes. We believe that this corresponds to a distinct complex,
not previously detected; a possible assignment is the for-
mation of a VIVO–hTF bound species involving vanadate as a
synergistic anion.
The reason why in the presence of FeIII the spectroscopic
CD and EPR signals of VIVO present disappear relatively fast
(much faster than in its absence) is not clear. A plausible
explanation is that in the presence of FeIII some of the VIVO is
removed from the stronger hTF binding sites, which increases
the relative amount of VIVO not bound to the protein. As the
pH of the solution is 7.4, this non-hTF-bound VIVO may be
easily oxidized even if the amount of O2 present is very low. If
the amount of O2 increases, e.g. by removing the stoppers of
the cell, the oxidation proceeds much faster. Addition of gluta-
thione to the solution does not promote the reduction of the
VV-species formed back to VIV (see the ESI-8† section). This
relatively fast oxidation in the presence of O2 occurs even if
there is enough hTF to bind all VIVO and all FeIII present.
The implications of these observations for in vivo con-
ditions cannot be anticipated easily. There are no reports
stating that the oxidation of VIVO may proceed in blood. In
contrast, it is usually assumed that VIVO-species are stabilized
and protected from oxidation by the presence of several bio-
logical reducing agents.61,79 A possible explanation is that
vanadate may act as a synergistic anion for FeIII (and possibly
also for VIVO) binding to hTF, this being a driving force for the
Fig. 13 Amplification of the low and high field ranges of the first derivative
EPR spectra of frozen solutions containing the reagents indicated for each
spectrum, ChTF ≈ 0.75 mM, in Hepes-S buffer of pH = 7.4 (see also Fig. S-8-2 and
-3†). (1) [hTF : VIVO : Fe] (1 : 2 : 0.6); (2) [hTF : VIVO : mhcpe : Fe] (1 : 1.4 : 2.8 : 0.6);
(3) [hTF : VIVO : mhcpe : Fe] (1 : 1.4 : 2.8 : 0.6) t = 60 min; (4) [hTF : VIVO :mhcpe]
(1 : 1.4 : 2.8); (5) [hTF : VIVO :mhcpe] (1 : 1 : 2); (6) [hTF : VIVO : mhcpe]
(1 : 0.6 : 1.2); (7) [VIVO : mhcpe] (1 : 2) CVO = 1 mM. All spectra correspond to
solutions frozen shortly after their preparation (except spectrum 3). The corres-
ponding 1st derivative EPR full spectra are depicted in Fig. S-8-2.† Spectra 1–3
are amplifications of the VIVO-EPR spectra of Fig. 12 (with the same numbering).
The spin Hamiltonian parameters obtained by simulation of these EPR spectra
are summarized in Table 5.
Fig. 12 First derivative EPR spectra of frozen solutions containing (1) apo-hTF
(ChTF = 0.75 mM), V
IVOSO4 (CVO ∼ 1.50 mM) and FeIII (CFe = 0.45 mM) in Hepes-S
buffer, the hTF : VIVO : FeIII molar ratio thus being 1 : 2 : 0.6; (2) a solution of CD
spectrum 5 of Fig. S-8-1;† (3) a solution of CD spectrum 11 of Fig. S-8-1,† i.e.
the same solution after 1 h. See also spectra 1–3 of Fig. 13.
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partial oxidation of VIVO. Further studies are being carried out
to understand the processes taking place in these systems.
Interaction of vanadium–mhcpe complexes with human
serum albumin
Fig. 14 depicts CD spectra of solutions containing HSA (grey
spectrum, which may be considered as the baseline), and of
solutions containing HSA, VIVOSO4 and mhcpe in the
400–1000 nm range. The CD spectra of solutions containing
HSA and VIVOSO4 differ from those of solutions containing
HSA, VIVOSO4 and mhcpe. Namely, the λmax of the two main
bands observed in the 400–1000 nm range differ, and the
|Δε| values are much higher, by a factor of ca. 7, when
mhcpe is present in solution. The rather high |Δε| values
observed indicate that mhcpe promotes the binding of VIVO to
HSA; it is probable that the binding takes place with VIVO
bound to more than one protein residue, e.g. Nimidazole atoms
of His residues, Ocarboxylate atoms of Asp residues, or others.
Fig. SI-9-1† depicts CD spectra in the 200–250 nm range of
a solution containing HSA, and of this after stepwise additions
of a solution containing VIVOSO4 and mhcpe in a 1 : 2 molar
ratio. Upon addition of this solution of VIVO(mhcpe)2 up to a
molar ratio of 1 : 1 : 2 (HSA : VIVO :mhcpe), the CD spectrum
shows no change. Upon further additions of the VIVO(mhcpe)2
solution, the pattern of the CD spectra does not change, but
the |Δε| values globally increase. As mhcpe and VIVO–mhcpe
complexes absorb in this wavelength range, ICD bands may be
responsible for the increase in the Δε values. Thus, we cannot
conclude with certainty that upon addition of a complex there
are conformational changes of the protein; probably these
changes take place but are not very extensive.
Interactions of vanadium–mhcpe complexes with hTF and
HSA with concentrations close to those expected in blood
plasma
In the UV region, namely in the 290–390 nm range, HSA has a
negative band up to ca. 330 nm, and the Δε values are ca. zero
for λ > 330 nm. Fig. 15 depicts the changes observed upon
adding a solution containing VIVOSO4 and mhcpe (1 : 2 molar
ratio) trying to simulate in vivo conditions, where it is likely
that the concentration of VIVO or VIVO-complexes will not be
higher than 80 μM (possibly it will be lower, except for short
periods if VIVO-complexes are introduced by injection). The
changes observed are significant, i.e. VIVO–mhcpe complexes
bind to HSA and this yields very small changes in the CD
spectra in this wavelength range, namely at ca. 320–350 nm
where mhcpe presents a relatively strong band (see Fig. 2).
Fig. 16A depicts CD spectra of solutions containing HSA
and hTF in concentrations close to those present in human
blood plasma. Spectrum (a) corresponds to the CD signal for
the solution containing the two proteins, and (b–e) after step-
wise additions of a solution containing VIVOSO4 and mhcpe in
a 1 : 1 molar ratio. The spectra of Fig. 15 and 16A differ signifi-
cantly and clearly indicate that hTF is the main VIVO-binder,
ternary (at least) hTF–VIVO–mhcpe species being formed. In
fact, comparing what is depicted in Fig. 15, 16A and 16B, the
changes observed in Fig. 16A are indeed very similar to those
observed in solutions only containing hTF and VIVOSO4,
namely the clear observation of the strong ICD band of mhcpe
with λmax at ca. 330 nm. Quite similar observations were made
with solutions containing HSA (0.630 mM) and hTF (40 μM)
and adding VIVO(dhp)2 or V
IVO(maltol)2 (see the section
ESI-6†). For these simulated human blood plasma conditions,
hTF is again the main VIVO-binder, with ternary (at least) hTF–
VIVO–dhp or –maltol species also being formed.
Clearly, as in the case of the solutions containing amino
acids or dipeptides (see above), the formation of ternary
species HSA–VIVO–mhcpe enhances the interaction of the
metal ion with chiral groups of the protein, the intensity of the
ICD bands due to VIV d–d transitions increasing. Sanna
Fig. 14 CD spectra of HSA (0.650 mM) solution (dark grey) and after stepwise
additions of a solution containing VIVOSO4 and mhcpe in a 1 : 1 molar ratio in
Hepes-CL buffer at pH 7.4. The HSA : VIVOSO4 : mhcpe molar ratios are as indi-
cated: a: (1 : 0.5 : 0.5); b: (1 : 1 : 1); c: (1 : 1.5 : 1.5); d: (1 : 2 : 2); e: (1 : 3 : 3); f:
(1 : 4 : 4); g: (1 : 5 : 5). The spectra were recorded with a 50 mm optical path
quartz cell (section ESI-4†).
Fig. 15 CD spectra of (a) a solution containing HSA (0.630 mM), and (b) a solu-
tion containing HSA (0.630 mM), VIVOSO4 (80 μM) and mhcpe (160 μM) in
Hepes-S buffer at pH 7.4. The spectra were recorded with a 2 mm optical path
quartz cell. The change in signal in the range 310–350 nm from spectrum (a) to
(b) is significant and is probably due to an induced CD band of the mhcpe ligand.
The difference between the two spectra is the grey curve labelled with ‘△’.
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et al.,46 in the case of dhp, suggested the formation of VIVO-
(dhp)2–HSA ternary species, with the V
IVO-unit bound to a his-
tidine residue, and a similar species VIVO(maltol)2–HSA was
predicted in the case of maltol. We cannot rule out the for-
mation of the similar species VIVO(mhcpe)2–HSA in the
present system; however, the CD spectra of Fig. 14 totally differ
from those of solutions containing VIVOSO4 and histidine,
73
and from solutions containing VIVOSO4, histidine and mhcpe.
The CD spectra also totally differ for the HSA and hTF systems,
indicating that distinct species should be formed and not just
VIVO(carrier)2–protein species.
Transport of vanadium–mhcpe complexes in blood
If the compound is taken orally, a significant amount of VIVO–
mhcpe complexes may be present at the pH of the stomach, as
inferred from the obtained speciation diagram (Fig. 4), but
presently it is not possible to anticipate if the VIVO–mhcpe
complexes will be extensively absorbed in the gastro-intestinal
tract or not.
The models described indicate that when VIVO–mhcpe com-
plexes are introduced into the blood stream, the VIVO moiety
will preferentially bind to hTF forming hTF–VIVO–mhcpe com-
plexes. However, thermodynamic models correspond to equili-
brium conditions and these cannot be unambiguously applied
to living systems. If only thermodynamic considerations are
assumed, it may be anticipated that if a small amount of a
solution containing VIVO–mhcpe complexes is injected into
blood, the metal ion is transported by hTF mainly as (VIVO)
(hTF)(mhcpe) and (VIVO)2(hTF)(mhcpe)2 complexes.
Conclusions
A new pyrimidinone, mhcpe (HL), was synthesized, its struc-
ture determined by single crystal X-ray diffraction and its acid–
base properties were studied by potentiometric and spectro-
photometric methods, as well as by DFT calculations. The
most stable structure for each of the H2L
+, HL and L− forms
in aqueous solution was established, thus enabling the
assignment of the groups involved in the protonation/de-
protonation processes: a proton bound to a N-ring atom in
the case of Ka1 and an O-catecholate-type proton in the case of
Ka2.
Aqueous solution studies regarding the identification and
characterization of complexes formed by VIVO2+ and mhcpe
were carried out in the pH range 2–11 using potentiometry,
EPR and UV-Vis techniques. An equilibrium model was estab-
lished as well as the binding modes corresponding to each
stoichiometry. The mhcpe− ligand forms quite stable com-
plexes with VIVO2+, the global binding ability being similar to
that of maltol− and lower than that of dhp−. The possibility of
formation of ternary complexes VIVO–mhcpe-L′ with several
amino acids was confirmed.
The interaction of V–mhcpe complexes with human plasma
proteins (transferrin and albumin) was evaluated. In the case
of transferrin the mhcpe ligand is involved in the binding of
VIVO2+ to the protein, the most important species formed cor-
responding to (VIVO)(hTF)(mhcpe) and (VIVO)2(hTF)(mhcpe)2.
Strong induced CD-signals were recorded for mhcpe-intra-
ligand CD bands as well as ICD in d–d transitions of VIV, indi-
cating that these VIV–mhcpe ternary species are in close inter-
action with chiral groups of the iron binding site of hTF;
similar bands were also recorded for (VIVO)n(hTF)(maltol)m
and (VIVO)n(hTF)(dhp)m ternary complexes.
57
VIVO–HSA–mhcpe species may also form and were ident-
ified by both EPR and CD spectra. However, CD spectra
recorded under conditions close to those existing in human
blood serum, namely with a concentration of HSA of ca.
630 μM and hTF of ca. 40 μM, up to a total vanadium concen-
tration of 80 μM, indicate that VIVO–mhcpe species bind
Fig. 16 CD spectra of (A) HSA–hTF–VIVO–mhcpe solutions: a solution containing HSA (0.630 mM) and hTF (40 μM) (a) and after stepwise additions of a solution
containing VIVOSO4 and mhcpe in a 1 : 1 molar ratio in Hepes-S buffer at pH 7.4: the concentrations are as indicated: (b) 630 μM HSA + 40 μM hTF + 40 μM VIVO-
(mhcpe)2; (c) 630 μM HSA + 40 μM hTF + 80 μM VIVO(mhcpe)2; (d) 630 μM HSA + 40 μM hTF + 160 μM VIVO(mhcpe)2; (e) 630 μM HSA + 40 μM hTF + 320 μM VIVO-
(mhcpe)2. (B) hTF–V
IVO–mhcpe solutions: (a) 100 μM hTF; (b) 100 μM hTF + 100 μM VIVO(mhcpe)2; (c) 100 μM hTF + 200 μM VIVO(mhcpe)2; (d) 100 μM hTF +
300 μM VIVO(mhcpe)2; (e) 100 μM hTF + 500 μM VIVO(mhcpe)2. The spectra were recorded with a 2 mm optical path quartz cell.
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mainly to hTF. Similar conclusions are made in the case of
maltol and dhp. For higher vanadium concentrations HSA may
start being a relevant VIVO-binder.
When FeIII is present or is added to solutions containing
hTF, VIVO2+ and mhcpe, the FeIII binds hTF removing an equi-
valent number of VIVO-complexes, and EPR spectra clearly
show both the signals of FeIII–hTF and of VIVO–hTF species.
However, in the presence of FeIII the EPR and CD spectroscopic
signals due to VIVO disappear much faster than in its absence,
and a significant amount of VV–hTF species is detected by 51V
NMR in the obtained solutions.
In conclusion, the newly synthesized compound mhcpe is a
suitable carrier ligand for VIVO, being able to engage the metal
ion in stable complexes and assisting its transport in blood
plasma conditions through transferrin binding with the for-
mation of ternary species involving the VIVO metal ion, mhcpe
and transferrin. Binding to mhcpe does not modify the prefer-
ence of VIVO2+ for transferrin despite the major concentration
of albumin available in blood plasma conditions. These inter-
actions may be of relevance for the cellular uptake of VIVO
mediated by the transferrin receptor.
Experimental section
Synthesis
Synthesis of benzyl benzyloxyacetate.80 A suspension of
sodium hydride (1.18 g, 60% in oil, 30 mmol) in dry THF
(20 mL) was added to benzyl alcohol (3 g, 30 mmol) at 0 °C.
Benzyl bromoacetate (6.9 g, 30 mmol) was added dropwise.
After being stirred for 24 hours, the reaction mixture was
poured into water and extracted twice with ether. The com-
bined organic extracts were dried over anhydrous Na2SO4/
H2SO4 (conc.). Purification on a silica gel column (hexane–
ethyl acetate 6 : 1) yielded the title compound as an oil.
Yield: 76%. 1H NMR (CDCl3, δ): 7.38 (m, 10H, Ph); 5.22 (s, 2H,
Ph-CH2-OCO); 4.65 (s, 2H, Ph-CH2-OCH2); 4.16 (s, 2H,
OCO-CH2-O).
Synthesis of 2-methyl-3H-5-benzyloxy-6-carboxy-4-pyrimidi-
none ethyl ester. (Adapted from ref. 41.) Benzyl-2-(benzyloxy)-
acetate (14.13 g, 55.13 mmol), diethyloxalate (8.06 g,
55.13 mmol), and ethanol (0.2 mL) were dissolved in dry THF
(100 mL). NaH (2.34 g, 60% in oil, 58.5 mmol) was added and
the mixture was stirred at room temperature for 48 h. THF
was removed under vacuum, and the residue was dissolved in
ethanol (100 mL), followed by addition of sodium ethoxide
(3.75 g, 55.1 mmol) and acetamidine hydrochloride (5.21 g,
5.11 mmol). After stirring at 60 °C for 14 h, the resulting sus-
pension was cooled to room temperature, and most of the
solvent removed under vacuum. The resulting oil was
extracted with CH2Cl2 and H2O. The pH of the aqueous phase
was adjusted to ∼6 with HCl (conc.) and both phases were
washed several times. The organic phase was separated, dried
with anhydrous Na2SO4 and the CH2Cl2 evaporated till an
orange oil was obtained. This was immediately shaken with
diethyl ether (30 mL) and left in the freezer. A white solid
precipitated, filtered, and 4.3 g of 2-methyl-3H-5-benzyloxy-6-
carboxy-4-pyrimidinone ethyl ester were obtained. The
residual oil was separated by chromatography (silica gel) with
a mixture of ethyl acetate and CH2Cl2 (1 : 1) and 2.1 g
2-methyl-3H-5-benzyloxy-6-carboxy-4-pyrimidinone ethyl ester
were additionally obtained. Yield: 40.5%. M.p.: 125–126 °C.
Elemental analysis: found (calc. for C15H16N2O4): C, 62.5
(62.5); H, 5.6 (5.6); N, 9.7 (9.7). Mass spectrometry (FAB-MS+,
thioglycerol matrix): 289 amu [C15H17N2O4]
+. 1H NMR (CDCl3,
200 MHz, 293 K, δ): 12.84 (br s, 1H, amide NH), 7.46 (m, 2H,
Ph), 7.37 (m, 3H, Ph), 5.28 (s, 2H, CH2-Ph), 4.37 (q, 2H, J = 7.1
Hz, OCH2), 2.51 (s, 3H, 2-Me), 1.34 (t, 3H, J = 7.1 Hz, CH2-
Me).
Synthesis of 2-methyl-3H-5-hydroxy-6-carboxy-4-pyrimidi-
none ethyl ester (1, mhcpe). The 2-methyl-3H-5-benzyloxy-6-
carboxy-4-pyrimidinone ethyl ester (0.600 g, 2.08 mmol) was
dissolved in acetic acid (20 mL) and Pd/C 5% (30 mg) was
added to the solution. This mixture was stirred vigorously
under a H2 atmosphere for 8 h at room temperature. After Pd/C
filtration, a precipitate was obtained from the solution by
partial evaporation of the solvent. This precipitate was dis-
solved in methanol. The white solid obtained from this metha-
nolic solution is mhcpe, 1, (0.22 g; yield: 53.4%). Crystals from
the solution suitable for X-ray diffraction were obtained.
Elementary analysis: found (calc. for C8H10N2O4): C, 48.2
(48.5); H, 5.0 (5.1); N, 14.0 (14.1). M.p.: 220–222 °C. Mass spec-
trometry (FAB-MS+, 3-NOBA matrix): 199 amu. [C8H11N2O4]
+.
1H NMR (CDCl3, 200 MHz, 293 K, δ): 12.76 (br s, 1H, amide
NH), 10.82 (br s, 1H, OH), 4.52 (q, 2H, J = 7.3 Hz, O-CH2-Me),
2.51 (s, 3H, 2-Me), 1.46 (t, 3H, J = 7.1 Hz, ester CH3);
13C NMR
(CDCl3, 500 MHz, 293 K, δ): 169.7 (COOEt), 160.5 (pyrimidi-
none N-C-2-Me-N), 149.2 (pyrimidinone CvO), 148.2 (pyrimi-
dinone C-OH), 127.5 (pyrimidinone N-C-COH), 63.3 (O-CH2-
Me), 21.5 (pyrimidinone 2-Me), 14.2 (ester group CH3).
Synthesis of 2,3-dimethyl 5-benzyloxy-6-carboxy-4-pyrimidi-
none ethyl ester (2, dbcpe). A solution of 1 (4.88 g, 16.9 mmol)
in DMF (20 mL) was added dropwise to a stirred suspension of
NaH (0.745 g, 60% in oil, 18.6 mmol) in dry DMF (20 mL) over
∼20 min maintaining gentle effervescence. After H2 evolution
had ceased, methyl iodide (1.27 mL, 20.4 mmol) was added in
one portion and the reaction mixture was stirred at room
temperature during 4 h. The excess hydride was quenched
with ethanol (2 mL), and DMF was removed by rotary evapor-
ation under vacuum. Addition of water produced an oily ‘solid’
which became an off-white crystalline mass upon further
shaking. This solid was separated by filtration, dried briefly,
and then washed with hexane (3 × 20 mL) to afford 3.0 g
(∼10 mmol) of crude 2,3-dimethyl-5-benzyloxy-6-carboxy-4-pyr-
imidinone ethyl ester (2, dbcpe). This crude product was
recrystallized in chloroform and crystals of dbcpe suitable for
X-ray diffraction were obtained. Yield: 58.8%. 1H NMR (CDCl3,
200 MHz, 293 K, δ): 7.47–7.33 (m, 5H, Ph), 5.25 (s, 2H, CH2-
Ph), 4.34 (q, 2H, J = 7.1 Hz, O-CH2), 3.56 (s, 3H, 3-NMe), 1.32
(t, 3H, J = 7.1 Hz, CH2-Me).
Synthesis of 2,3-dimethyl-5-benzyloxy-6-carboxy-4-pyrimidi-
none (4, HOPY acid). (Adapted from ref. 41.) ∼3.0 g of
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dbcpe and KOH (0.666 g; 11.8 mmol) were dissolved in
methanol (50 mL) and stirred at room temperature. After 6 h
the hydrolysis was complete, and a fine yellow-white
precipitate had formed. After evaporation of the solvent the
residue was dissolved in water (20 mL), filtered and slowly
acidified with concentrated HCl. At pH ∼ 4 a small amount of
yellow precipitate was separated. At pH ∼ 2 a white precipitate
was isolated by filtration and washed with water. After
drying under vacuum, 2.6 g of 2,3-dimethyl-5-benzyloxy-6-
carboxy-4-pyrimidinone (4, HOPY acid; yield: 95.6%) were
obtained. Elemental analysis: found (calc. for C14H14N2O4):
C, 61.3 (61.5); H, 5.1 (5.1); N, 10.3 (10.2). M.p.: 179–180 °C.
1H NMR (CDCl3, 200 MHz, 293 K, δ): 7.53 (m, 3H, Ph), 7.36 (m,
2H, Ph), 5.49 (s, 2H, CH2-Ph), 3.57 (s, 3H, 3-NMe), 2.56 (s, 3H,
2-Me).
Synthesis of N-methyl-2,3-dimethyl-5-benzyloxy-6-carboxy-
amido-4-pyrimidinone. Carbonyl diimidazole (0.625 g,
3.86 mmol) was added in several portions during 10 min to a
slurry of HOPY acid (4, 1 g, 3.63 mmol) in CH2Cl2 (10 mL).
After a further 5 min period, methylamine (0.113 g, 1.82 mL of
2 M THF solution, 3.63 mmol) mixed with 5 mL of CH2Cl2 was
added dropwise during 5 min, and the reaction mixture was
stirred for 12 h. The CH2Cl2 was removed and the resultant oil
shaken with ethanol–diethyl ether (1 : 10). The white precipi-
tate obtained was filtered and washed with diethyl ether.
Yield, 51.8%. Elemental analysis: found (calc. for C15H17N3O3):
C, 62.9 (62.7); H, 6.0 (6.0); N, 15.1 (14.6). M.p.: 62–63 °C. Mass
spectrometry (FAB-MS+, 3-NOBA matrix): 288 amu
[C15H18N3O3]
+. 1H NMR (CDCl3, 200 MHz, 293 K, δ): δ
7.74–7.33 (m, 5H, Ph), 7.09 (s, 1H, NH-amide), 5.28 (s, 2H,
CH2-Ph), 3.57 (s, 3H, 3-NMe), 2.88 (d, 3H, J = 4.9 Hz, NH-Me),
2.54 (s, 3H, 2-Me); 13C NMR (CDCl3, 500 MHz, 293 K, δ): 163.4
(CONH), 160.5 (pyrimidinone N-C-2-Me-N), 153.3 (pyrimidi-
none CvO), 142.1 (pyrimidinone C-amide), 140.5 (Ph group
CH2-C), 136.3 (NCCvO), 129.0–128.6 (5C, Ph), 74.9 (O-CH2-
Ph), 31.8 (1C, 3-NMe), 23.2 (pyrimidinone 2-Me).
Synthesis of N-methyl-2,3-dimethyl-5-hydroxy-6-carboxy-
amido-4-pyrimidinone (N-MeHOPY, 3). N-Methyl-2,3-dimethyl-
5-benzyloxy-6-carboxyamido-4-pyrimidinone (0.500 g,
1.74 mmol) was dissolved in acetic acid (20 mL) and Pd/C 5%
(30 mg) was added to the solution. This mixture was stirred
vigorously under a H2 atmosphere for 4 h at room temperature.
After Pd/C filtration, an oil was obtained from the solution by
partial evaporation of the solvent and was precipitated with
hexane. A white precipitate of N-MeHOPY (3) was isolated by
filtration and was washed with hexane. Crystals of N-MeHOPY
suitable for X-ray diffraction were grown in acetic acid–hexane
(1 : 4) solution at low temperature. Yield: 32.0%. Elemental
analysis: found (calc. for C8H11N3O3): C, 48.9 (48.7); H, 5.8
(5.6); N, 21.8 (21.3). M.p.: 163–164 °C. Mass spectrometry
(FAB-MS+, 3-NOBA matrix): 198 amu [C8H12N3O3]
+. 1H NMR
(CDCl3, 200 MHz, 293 K, δ): 12.03 (br s, 1H, OH), 7.65 (br s,
1H, NH amide), 3.56 (s, 3H, 3-NMe), 3.0 (d, 3H, J = 4.9 Hz,
NH-Me), 2.46 (s, 3H, 2-Me); 13C NMR (CDCl3, 500 MHz, 293 K,
δ): 168.2 (CONH), 158.8 (pyrimidinone N-C-2-Me-N), 148.0
(pyrimidinone C-amide), 146.5 (pyrimidinone CvO), 125.37
(pyrimidinone C-OH), 31.8 (3-NMe), 25.7 (NH-Me), 22.7 (pyri-
midinone 2-Me).
Determination of protonation and formation constants of
mhcpe and VIVO–mhcpe systems
pH-potentiometric titrations. All measurements were made
in aqueous solution. The purity of the ligand was checked pH-
potentiometrically and the exact concentrations of solutions
were determined by checking the inflection points of the titra-
tions by the Gran method. Two stock solutions of VIVO(ClO4)2
were used and their VIVO2+ and H3O
+ concentrations were
determined and standardized as reported earlier62,81 by pH-
potentiometry. The VIVO2+ concentrations were ca. 300 mM
and ca. 180 mM and dilutions were made as appropriate. The
VV stock solution (∼30 mM) was prepared by dissolving KVO3
(Sigma-Aldrich) in an accurately measured volume of a KOH
solution of known molarity (0.2034 M), and its OH− concen-
tration was calculated taking into account the total volume of
the vanadate stock solution prepared.
All solutions were manipulated in an inert atmosphere
(high purity N2). The ionic strength was adjusted to 0.20 M KCl
and the temperature was 25.0 ± 0.1 °C. The pH was measured
with a Thermo Orion 420A+ pH-meter with a Mettler Toledo
U402-M3-S7/200 combined electrode, calibrated for hydrogen
ion concentration as described earlier.62 The ionic product of
water was pKw = 13.72.
Determination of protonation constants. For the determi-
nation of the protonation constants several sets of UV absorp-
tion spectra (210–380 nm) with concentrations of ca. 10−4 M
were measured in the pH range ca. 0.5 to 12, and five pH titra-
tion curves were also measured in the pH range ca. 1.8 to 12.
An individual calibration curve EMF vs. [H+] was established
for pH values < ∼2, valid for the present medium and electro-
des. For this purpose a set of HCl solutions were prepared with
known H+ concentration, from pH ca. 0.8 to 2.0, all with an
ionic strength of 0.20 M. The protonation constant β2 of
mhcpe was determined from the five titration curves of 10 to
15 mL samples, with initial concentrations in the range 0.0032
to 0.012 M, using the SUPERQUAD computer program.82 Both
protonation constants β1 and β2 of MHCPE were determined
from the UV spectra in the pH range 0.8 to 8 using the
PSEQUAD computer program.59 The calculated pKa values
determined from the UV spectra were pKa1 = 1.14 and pKa2 =
6.34. The pKa2 calculated from the pH-metric titration is 6.36.
Determination of formation constants. For the determi-
nation of the stability constants of the VIVO–mhcpe system
several sets of visible absorption spectra (350–900 nm) were
measured in the pH range ca. 0.7 to 12: (i) CVO ∼ 0.003 M
and L : M = 1.77 (from pH 2.5 to 8.0 and pH ∼ 11.8); (ii) CVO
∼ 0.005 M and L :M = 2.76 (from pH 0.98 to 9.9); (iii) CVO ∼
0.006 M and L :M = 3.05 (from pH 1.8 to 8.4); (iv) CVO ∼
0.009 M and L :M = 1.41 (from pH 2.1 to 8.8); (v) at pH ∼ 7.2
from CVO ∼ 0.0027 to ∼ 0.0091 M with CMHCPE ∼ 0.0182
M. Several pH-metric titrations were also carried out with
12.0 mL samples with total oxovanadium(IV) concentrations
in the range 0.002–0.0055 M, and L :M ratios from 1.0 to 4.6.
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These titrations were normally done from pH 1.8 up to 10,
unless very extensive hydrolysis or very slow equilibration was
detected (this only for L : M = 1.0, for pH ≥ 4.0), with a KOH
solution of known concentration (ca. 0.2 M) under a N2
atmosphere in thermostatized cells. The stock VIVO(ClO4)2
solutions used were the same as for the spectrophotometric
titrations.
The concentration stability constants βpqr = [MpLqHr]/
[M]p[L]q[H]r were calculated using the SUPERQUAD82 and the
PSEQUAD59 computer programs. The formation of the fol-
lowing VIVO–hydroxo complexes was taken into account:
[VIVO(OH)]+, [(VIVO)2(OH)2]
2+, [(VIVO)2(OH)5]
− and [VIVO-
(OH)3]
−. As is discussed in ref. 61 and 62 the log β of
[(VIVO)2(OH)5]
− and [VIVO(OH)3]
− are not known accurately;
thus the calculations for pH > 4 may not be entirely reliable,
particularly for systems and experimental conditions where
these VIVO–hydroxo complexes have significant
concentrations.
Conditional stability constants of apo-hTF–VIVO–mhcpe
species at pH 7.4. For all experiments a stock VIVO(SO4) solu-
tion was used (ca. 100 mM), which was diluted as appropriate.
The conditional formation constants calculated for the VIVO–
apo-hTF system40 using the PSEQUAD computer program are:
log K1 = log β1 = 13.4 and log K2 = 11.9 (log β2 = 25.3) and corre-
spond to the reactions at pH 7.4 (n = 1 or 2):
nVIVO2þ þ apo-hTFprotonation state at pH¼ 7:4 ⇄ ðVIVOÞn–hTF
The hydrolytic constants of VIVO2+ (see above) were taken
into account in the calculations.
The conditional formation constants Kpqr calculated for the
VIVO–apo-hTF–mhcpe system correspond to the reactions at
pH 7.4 (p,r = 1 or 2, q = 1):
pVIVO2þ þ q apo-hTFprotonation state at pH¼ 7:4
þ r mhcpe⇄ ðVIVOÞpðhTFÞqðmhcpeÞr
The hydrolytic constants of VIVO2+, the protonation con-
stants of mhcpe−, all formation constants of VIVO–mhcpe com-
plexes (see above) and the conditional stability constants for
the binary species (VIVO)–hTF and (VIVO)2–hTF
40 were taken
into account in the calculations for the VIVO–apo-hTF–mhcpe
system with the PSEQUAD computer program.
Spectroscopic measurements
Physical and spectroscopic studies. IR spectra were recorded
either with a BioRad FTS 3000 MX FTIR or with a Jasco FTIR
430 spectrometer. The CD spectra were recorded with a JASCO
720 spectropolarimeter, either with a red-sensitive photomulti-
plier (EXEL-308) suitable for the 400–1000 nm range or with
the photomultiplier suitable for the 170–700 nm range. Visible
spectra were recorded with a Hitachi U-2000 spectropho-
tometer. The EPR spectra were recorded at 77 K (on glasses
made by freezing solutions in liquid nitrogen) with a Bruker
ESP 300E X-band spectrometer. The 1H NMR and 51V NMR
spectra were obtained on a Bruker Avance III 400 MHz spectro-
meter at ca. 25 °C.
UV-Vis spectroscopy. All measurements with the mhcpe
solutions were made in water at I = 0.20 M KCl (for pH < 2
KCl–HCl mixtures with I = 0.2 M were used, see below). The
temperature was kept at 25.0 ± 0.3 °C with circulating water.
Unless otherwise stated, by visible (Vis) spectra we mean a re-
presentation of εm vs. λ [εm = absorption/(bCM), where b =
optical path and CM = total V
IV concentration]. The spectral
range covered was normally 210–390 nm (UV) or 350–900 nm
(Vis), with a 10 mm optical path quartz cell. Normally, but
not in all cases, the spectra were recorded changing the pH
with approximately fixed total vanadium and ligand
concentrations.
Circular dichroism. All measurements were made in water
and the temperature was kept at ca. 25.0 ± 1 °C. Unless other-
wise stated, by circular dichroism (CD) spectra we mean a re-
presentation of Δε values vs. λ [Δε: differential absorption/
(bCP) and CP = total protein concentration]. The spectral
range covered was either 190–250 nm (1 mm optical path) or
250–400 nm (2 or 10 mm optical path) or 400–1000 nm (10 or
50 mm optical path, section ESI-4†). All measurements and
operations of the spectropolarimeter were computer-con-
trolled, and the sample compartment was continuously flushed
with nitrogen gas.
EPR spectroscopy. In the absence of ethylene glycol or
DMSO a relatively broad background was present in most of
the frozen solution EPR spectra, therefore most spectra of solu-
tions containing VIVO2+ and mhcpe were run with aqueous
solutions containing 5% DMSO to promote the formation of a
good glass.
Several sets of EPR spectra were measured for the VIVO–
mhcpe system in the pH range ca. 0.7 to 12: (i) CVO ∼ 0.004 M
and L :M = 4.02 (from pH 7.4 to 11.3); (ii) CVO ∼ 0.005 M and
L :M = 2.76 (from pH 0.98 to 9.9); (iii) CVO ∼ 0.006 M and L : M
= 3.05 (from pH 1.8 to 8.4); (iv) CVO ∼ 0.007 M and L : M = 1.53
(from pH 7.6 to 11.0); (v) CVO ∼ 0.009 M and L :M = 1.41 (from
pH 2.1 to 8.8); (vi) at pH ∼ 7.2 from CVO ∼ 0.0027 to ∼ 0.0091
M with Cmhcpe ∼ 0.0182 M.
The EPR spectra help to elucidate which groups coordinate
in solution. For the VIVO-systems we used the additivity rule to
estimate the hyperfine coupling constant Az
est (see above). To
calculate the relevant spin-Hamiltonian parameters from the
experimental EPR spectra, these were either simulated using a
program from Rockenbauer and Korecz,63 or an iterative pro-
cedure developed by Chasteen et al.66 using the corrected
equations of Casella et al.83 was used.
1H and 51V NMR spectroscopy. All samples were prepared at
room temperature immediately before the acquisition of the
NMR spectra. Ligand solutions for the 1H NMR pH titrations
were prepared in D2O (99.995%D) weighting the appropriate
amount of the ligand in order to have the desired concen-
tration. When relevant the pD values of these solutions were
adjusted with DCl and CO2-free NaOD solutions, and
measured either on a Crison MicropH 2002 pH-meter with an
Ingold 405-M5 combined electrode, or using a Thermo Orion
420A+ pH meter with a Mettler Toledo U402-M3-S7/200 com-
bined microelectrode (all calibrated at 20 ± 1 °C with standard
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aqueous buffers at pH 4.0 and 7.0). The final values of pD were
determined from pD = pH* + 0.40, where pH* corresponds to
the reading of the pH meter.
For the acquisition of 1H NMR spectra to access protona-
tion steps of mhcpe a ∼5 mM solution of mhcpe was prepared
at pD ∼ 10 in D2O, by addition of CO2-free NaOD. The
measurements were done down to pH 1 by addition of DCl (or
NaOD, whenever necessary).
The 1H and 51V NMR chemical shifts were referenced rela-
tive to DSS (sodium 3-trimethyl-silyl-d4-propionate) at 0 ppm
and to external neat VOCl3 at 0 ppm, respectively.
51V NMR
acquisition parameters were: 33 kHz spectral width, 30 μs
pulse width, 1 s acquisition time and 10 Hz line broadening.
The signal intensities of the NMR resonances were obtained
using the line-fitting routine supplied with the NUTS™ PC-
based NMR spectral analysis program.
Preparation of solutions containing vanadium, apo-
transferrin, mhcpe and iron
Most samples containing VIVO were manipulated in a glove
bag purged with nitrogen or argon gas.
Hepes-S buffer. The composition of the Hepes-S buffer used
is 50 mM Hepes (Sigma-Aldrich), 25 mM carbonate added as
NaHCO3 (Sigma-Aldrich), 1 mM phosphate added as
NaH2PO4·H2O (Merck) and 0.20 mM KCl (Merck). This buffer
system was adjusted to a pH of 7.4 using conc. KOH.
Hepes-CL buffer. The composition of the Hepes-CL buffer
used is similar to that of Hepes-S, but additionally it also con-
tains: 0.1 mM citrate and 1.5 mM lactate. This buffer system
was also adjusted to pH 7.4 using conc. KOH. No clearly mea-
surable CD spectrum in the visible range (400–1000 nm) is
obtained with solutions of VIVOSO4 and mhcpe (1 : 1) in this
buffer; thus no ternary VIVO–lactate–mhcpe or VIVO–citrate–
mhcpe complexes can be detected by CD under these
conditions.
PBS buffer. Phosphate buffered saline (PBS) from Sigma-
Aldrich was used. One tablet dissolved in 200 mL of Milli-
pore® water yields 0.01 M phosphate buffer, 0.0027 M potass-
ium chloride and 0.137 M sodium chloride, pH 7.4, at 25 °C.
Every PBS solution used in this work also contains 25 mM
NaHCO3.
VIVO-solutions. For all experiments involving studies with
solutions containing serum proteins, a stock VIVO(SO4) solu-
tion was used (99.0 mM, pH ∼ 2), which was first diluted as
appropriate (e.g. to 9.90 mM or 0.990 mM), and then used in
the experiments.
Protein solutions. Human apo-transferrin solutions were
prepared by dissolving the protein, either transferrin (Sigma,
T4382) or human serum albumin (Sigma, A1653, fatted) in
buffer at pH 7.4. The solutions were allowed to stand for at
least 1 h to allow equilibration. During this period they were
gently swirled without strong agitation. The concentrations of
the protein solutions were determined by measuring the absor-
bance at 280 nm using an extinction coefficient of 92 300 M−1
cm−1 for apo-transferrin,40,84,85 and 36 850 M−1 cm−1 for
HSA.86,87 Normally argon was bubbled through all solutions
prior to use for measurements with VIV-complexes to displace
any oxygen that may be present, and the solutions were kept
and manipulated under an argon atmosphere inside a glove
bag.
Iron transferrin solutions were prepared by dissolving the
ferrous ammonium sulfate hexahydrate salt (Fe(NH4)2-
(SO4)2·6H2O, Mohr’s salt) in the apo-hTF solution in
buffer. The solution of Fe–hTF was kept for ca. 24 h so that
FeIII forms and binds to hTF yielding the FeIII–hTF complex.
For (Fe)2–hTF an extinction coefficient of 113 000 M
−1 cm−1
was used.51
Loading of FeIII onto hTF. Samples containing FeIII were
prepared from stock solutions of Mohr’s salt ((NH4)2Fe-
(SO4)2·6H2O). Normally to form holo-transferrin (orange solu-
tion), to saturate apo-transferrin with iron, apo-transferrin
solutions (colourless solution) were mixed with ferrous
ammonium sulfate hexahydrate in Hepes-S or Hepes-CL buffer
pH 7.4. The FeII, from the stock solution, is then rapidly oxi-
dized to FeIII in the presence of the protein and after degassing
the solution. FeCl3 (Merck) was used in some cases to prepare
solutions that were added to solutions containing apo-hTF
and/or VIVOSO4.
Several sets of CD (visible range) and EPR spectra were
measured for the VIVO–apo-hTF–mhcpe system, normally with
a transferrin concentration of 750 μM and varying the VIVO-
and mhcpe-concentration. 750 μM was an adequate VIVO con-
centration (and thus hTF concentration for 1 : 1 ratios) to
produce EPR spectra suitable for simulation. Most of these
spectra were measured with buffer solutions at pH = 7.4. Most
preparations were done under argon doing all manipulations
inside glove bags. The CD spectra were run either with 10 mm
or 50 mm optical path quartz cells (see ESI-4†) in the wave-
length range 400–1000 nm, and the sample compartment was
continuously flushed with nitrogen gas. Several CD spectra
were measured with human serum albumin (ca. 0.63 mM, the
HSA blood plasma concentration) varying the VIVO- and
mhcpe-concentration.
Several sets of CD spectra (UV range) were measured for the
VIVO–apo-hTF–mhcpe system, normally with a apo-transferrin
concentration of 100 μM and varying the VIVO- and mhcpe-
concentration, either using a 2 mm or a 10 mm optical path
quartz cells in the wavelength range 250–400 nm.
A few CD spectra (far-UV range) were measured for the
VIVO–apo-hTF, VIVO–albumin and VIVO–albumin–mhcpe
systems, normally with a protein concentration of ca. 5–10 μM
and varying the VIVO or the VIVO–mhcpe concentration
(section ESI-9†), using a 1 mm optical path quartz cell in the
wavelength range 190–250 nm.
Several sets of CD spectra (UV range) were measured for the
VIVO–apo-hTF–HSA–mhcpe system, with an albumin concen-
tration of 630 μM and a transferrin concentration of 40 μM
and varying the VIVO- and mhcpe-concentration. These spectra
were measured with Hepes-S buffer solutions at pH = 7.4 and
the preparations were done under argon doing all manipula-
tions inside glove bags. The CD spectra were run with a 2 mm
optical path quartz cell in the wavelength range 250–400 nm,
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and the sample compartment was continuously flushed with
nitrogen gas.
X-ray crystal structure determinations
Three-dimensional X-ray data were collected on a Bruker
SMART 1000 CCD diffractometer using a graphite monochro-
mator and Mo-Kα radiation (λ = 0.71073 Å) by the ϕ–ω scan
method (Table 6). Data were collected at room temperature.
Reflections were measured from a hemisphere of data col-
lected of frames each covering 0.3 degrees in ω. Of the 4415
for 1, 8387 for 2 and 5823 for 3 reflections measured, all of
which were corrected for Lorentz and polarization effects, and
for absorption by semi-empirical methods based on symmetry-
equivalent and repeated reflections, 985 for 1, 1502 for 2 and
1870 for 3 independent reflections exceeded the significance
level |F|/σ(|F|) > 4.0. Complex scattering factors were taken
from the program package SHELXTL.88,89 The structure was
solved by direct methods and refined by full-matrix least-
squares methods on F2. In 1, the hydrogen atoms were
included in calculated positions and refined in riding mode
except the hydrogen atom H(2O), which was located in the
difference Fourier map and freely refined; in 2, all of them
were included in calculated positions; in 3 all of them were
located in the difference Fourier map and freely refined.
Refinement converged with allowance for thermal anisotropy
of all non-hydrogen atoms. A weighting scheme w = 1/[σ2(Fo
2) +
(0.113100P)2] for 1, w = 1/[σ2(Fo
2) + (0.108600P)2 + 0.019500P]
for 2 and w = 1/[σ2(Fo
2) + (0.056900P)2 + 0.867500P] for 3,
where P = (|Fo|
2 + 2|Fc|
2)/3, were used in the later stages of
refinement. A final difference Fourier map showed no residual
density outside: 0.305 and −0.298 e Å−3 in 1, 0.222 and −0.236
e Å−3 in 2, 0.340 and −0.176 e Å−3 in 3. CCDC 926545, 926546
and 926547 contain the supplementary crystallographic data
for the structures reported in this paper.
DFT computational details. All calculations were carried out
using the GAUSSIAN 03 software package,90 and the PBE1PBE
functional, without symmetry constraints. That functional
uses a hybrid generalised gradient approximation (GGA),
including a 25% mixture of Hartree–Fock91 exchange with
DFT60 exchange–correlation, given by Perdew, Burke and Ern-
zerhof functional (PBE).92,93 The optimised geometries were
obtained with a standard 6-31G(d,p)94–98 basis set. A Natural
Population Analysis (NPA)99–104 and the resulting Wiberg
indices105 were used to study the electronic structure and
bonding of the optimised species. The energy differences
reported in Scheme 3 result from single point energy calcu-
lations using a 6-311++G(d,p)106–110 basis set and the geome-
tries optimised at the PBE1PBE/6-31G(d,p) level. Solvent
(water) effects were considered in the energy calculations,
using the Polarizable Continuum Model (PCM) initially
devised by Tomasi and coworkers111–113 as implemented in
GAUSSIAN 03.114,115 The molecular cavity was based on the
united atom topological model applied on UAHF radii, opti-
mized for the HF/6-31G(d) level.
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